Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Tony Carlsson"'
Autor:
Karolin Falconer, Christian Kampmann, Ola Weiland, Susanna Haverinen, Kristina Cardell, Simon B. Larsson, Stefan C. T. Svensson, Soo Aleman, Anders Nystedt, Ann-Sofi Duberg, Stephan Stenmark, Rune Wejstål, Habiba Kamal, Heiner Wedemeyer, Gabriel Westman, Tony Carlsson, Per Björkman
Background and aims Hepatitis delta virus (HDV) infection is associated with fast progression to liver cirrhosis and liver complications. Previous studies have, however, been mainly from tertiary care centers, with risk for referral bias toward patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::977a6d974c7f258e10875326d2234251
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-439127
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-439127
Autor:
Soo Aleman, Johan K. Sandberg, Karolin Falconer, Niklas K. Björkström, Jean-Baptiste Gorin, Tony Carlsson, Benedikt Strunz, David Malone
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-10 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-10 (2020)
Direct-acting antivirals (DAAs) have dramatically improved the management of chronic hepatitis C (CHC). In this study, we investigated the effects of hepatitis C virus clearance on markers of systemic inflammation measured in plasma samples from CHC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7655d60cbaed58bccbe49a2fda64e432
https://pubmed.ncbi.nlm.nih.gov/32034167
https://pubmed.ncbi.nlm.nih.gov/32034167
Publikováno v:
Perfusion. 25:305-312
Background: Antithrombin concentrate (AT) is used to treat heparin resistance (HR) in cardiac surgery. It is usually given slowly due to the fear of anaphylaxis. This may delay cardiac catheterisation and the start of cardiopulmonary bypass (CPB). HR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d235fe225f51962e1bee55860c2f311
https://doi.org/10.1177/0267659110377677
https://doi.org/10.1177/0267659110377677
Publikováno v:
Journal of Medical Virology. 80:803-807
Fifty consecutive patients with genotype 2 or 3 chronic hepatitis C were treated with peg-IFN alfa-2a 135 µg weekly and ribavirin (11 mg/kg body weight) daily during 24 weeks. Rapid viral response treatment week 4, end-of-treatment response, and sus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf6bc5e04685a007dfef7e912ac939fb
https://doi.org/10.1002/jmv.21133
https://doi.org/10.1002/jmv.21133
Autor:
Tony Carlsson, Åsa Parke, Erika Hörnfeld, Ola Weiland, Karin Lindahl, Lars Ståhle, Robert Schvarcz
Publikováno v:
Therapeutic drug monitoring. 37(6)
BACKGROUND The aim of the study was to investigate whether patients with a previous nonresponse to standard of care treatment with ribavirin dosed according to body weight would respond to a high individualized dose of concentration-monitored ribavir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f7be766850f2f180a2e9e2b028b9aeb
https://pubmed.ncbi.nlm.nih.gov/25811342
https://pubmed.ncbi.nlm.nih.gov/25811342
Autor:
Per Sangfelt, Ola Weiland, Tony Carlsson, E. Wallmark, Jonas Bläckberg, Olle Reichard, Gunnar Norkrans
Publikováno v:
Journal of Viral Hepatitis. 12:473-480
To optimize treatment of chronic hepatitis C early identification of patients who will not achieve a sustained virological response (SVR) is desirable. We investigated hepatitis C virus (HCV) RNA kinetics at day 1 (in 15 patients; genotypes 1 and non
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08092a2063ef3c7030ead7f852f7c0fd
https://doi.org/10.1111/j.1365-2893.2005.00621.x
https://doi.org/10.1111/j.1365-2893.2005.00621.x
Publikováno v:
Scandinavian Journal of Infectious Diseases. 35:180-185
Hepatitis C virus (HCV) RNA kinetics were studied at baseline weeks 4, 8 and 12 during interferon-alpha (IFN) monotherapy in 65 patients (mean age 39 y, range 19-66 y) with chronic HCV infection. IFN treatment was given either as initial induction (n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79551c59e86ec5ccb5cef91a165fdd65
https://doi.org/10.1080/003655400310000175
https://doi.org/10.1080/003655400310000175
Publikováno v:
Karolinska Institutet
We studied HCV kinetics during the first 84 d of interferon-alpha (IFN) treatment. IFN was administered either at a dose of 3 million units daily for the first 14 d and thereafter 3 times per week (t.i.w.) (induction treatment), or at a dose of 3 mil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4187fcaee60fbbfd8d54158b128de100
https://doi.org/10.1080/00365540110076615
https://doi.org/10.1080/00365540110076615
Autor:
Robert Schvarcz, Olle Reichard, S. Shev, Rune Wejstål, Ingrid Uhnoo, Karin Lindahl, Tony Carlsson
Publikováno v:
Journal of Viral Hepatitis. 7:409-413
Interferon (IFN) alpha in combination with ribavirin (RIB) is standard therapy for patients with chronic hepatitis C virus (HCV) infection. However, many patients do not respond with sustained HCV clearance to this therapy. At present, no accepted tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::961e182e7ce20dd4d17f7a234c70c47e
https://doi.org/10.1046/j.1365-2893.2000.00256.x
https://doi.org/10.1046/j.1365-2893.2000.00256.x
Autor:
Soo Aleman, Loa Davidsdottir, Fredrik Granath, Nina Rose, Anders Ekbom, Hans Verbaan, Hans Norrgren, Magnus Hedenstierna, Per Stål, Ola Weiland, Rolf Hultcrantz, Nogol Rahbin, Tony Carlsson
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 57(2)
Background. The long-term effect of sustained virologic response (SVR) to antiviral therapy on the risk of developing hepatocellular carcinoma (HCC), liver complications, liver-related death, and overall death in hepatitis C virus (HCV)–infected pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11e7f8cb748b8775ca8a115685ea94b4
https://pubmed.ncbi.nlm.nih.gov/23616493
https://pubmed.ncbi.nlm.nih.gov/23616493